Published in Gene Therapy Weekly, September 21st, 2006
Study 1: A study from the United States has documented a novel anti-inflammatory role for glycogen synthase kinase-3 beta (GSK-3 beta) in the inhibition of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta)-induced inflammatory gene expression.
"GSK-3 beta is a Ser/Thr kinase with a broad array of cellular targets, such as cytoskeletal proteins and transcription factors. Recent studies with GSK-3 beta-null mice showed impaired NF kappa B-mediated survival responses.
"Because NF kappa B serves a dual role as a key regulator of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.